Catabasis Pharmaceuticals has shared the latest edition of their community newsletter. Their plan is to share top-line results from the Phase 3 PolarisDMD trial of edasalonexent with the Duchenne community later this year. As highlighted in the newsletter, Catabasis intends to immediately share these results in both their newsletter and in a press release on social media. Following the release of the results PPMD will host a webinar in partnership with Catabasis. Please review the newsletter to learn more.